PuraPharm Corporation Limited (stock code: 1498) held an Extraordinary General Meeting (EGM) on 24 October 2025 at 10:00 a.m. All ordinary resolutions related to the Patent Licence Agreement and the Subscription Agreement were passed by way of poll. Each resolution garnered 60,564,344 votes in favor and no votes against, resulting in a 100% approval rate.

The total number of issued shares on the date of the EGM was 395,897,275, with 166,418,793 shares (approximately 42.04% of total issued shares) entitled to vote on the relevant resolutions. Certain shareholders, including those holding ultimate beneficial interests in the Licensor, were required to abstain from voting. The trustee of the Share Award Scheme, holding 844,335 shares, also abstained from voting on the matters under the Listing Rules.

Computershare Hong Kong Investor Services Limited acted as the scrutineer. Several directors of PuraPharm, including the chairman, attended the EGM either in person or by electronic means. All passed resolutions are deemed duly approved as ordinary resolutions of the company.